Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Cancers|April 13, 2024
Neo-Adjuvant Therapy for Metastatic MelanomaAnke M J Kuijpers, Alexander C J van Akkooi
Microsurgery|March 11, 2025
Objectifying Clinical Outcomes After Lymphaticovenous Anastomosis and Vascularized Lymph Node Transfer in the Treatment of Extremity Lymphedema: A Systematic Review and Meta-AnalysisBrett A Hahn, Alieske Kleeven, Milan C Richir, et al.
Annals of Surgical Oncology|December 18, 2025
Independent Dutch Validation Study of CP-GEP (Merlin Assay) for the Prediction of Nodal Metastasis and Long-Term Outcome in Patients with Primary Cutaneous MelanomaLisanne P Zijlker, Zahra Verwer, Bart A van der Wiel, et al.
Surgical Oncology|July 11, 2025
The Qaly study: Quality of life and lower extremity lymphedema in 174 patients after inguinal lymphadenectomyBrett A Hahn, Alieske Kleeven, Milan C Richir, et al.
World Journal of Surgery|September 24, 2014
Implementation of a standardized HIPEC protocol improves outcome for peritoneal malignancyAnke M J Kuijpers, Arend G J Aalbers, Simon W Nienhuijs, et al.
European Journal of Cancer (Oxford, England : 1990)|March 27, 2026
Predictive value of [<sup>18</sup>F]FDG PET/CT and index lymph node response following neoadjuvant pembrolizumab in resectable stage 3 melanoma: Real world data from the largest melanoma centres in the NetherlandsMichael J Wilson, Antonius W Schurink, Yvonne Schrage, et al.
Frontiers in Endocrinology|May 23, 2022
Long-Term Oncological Outcomes of Papillary Thyroid Cancer and Follicular Thyroid Cancer in Children: A Nationwide Population-Based StudyDaniël J van de Berg, Anke M J Kuijpers, Anton F Engelsman, et al.
Annals of Surgical Oncology|July 31, 2013
Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocolAnke M J Kuijpers, Boj Mirck, Arend G J Aalbers, et al.
Annals of Surgical Oncology|October 14, 2025
International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III MelanomaElan Novis, Mervi Rautalin, Rodabe N Amaria, et al.
The New England Journal of Medicine|June 3, 2024
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III MelanomaChristian U Blank, Minke W Lucas, Richard A Scolyer, et al.
Pageof 1